Open House Originale Rabattverträge 2025-16 - Empagliflozin
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-16 - Empagliflozin
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated contract value is disclosed, making it impossible to assess potential revenue.
Contract ends automatically upon patent expiry or loss of market exclusivity, which could shorten the contract term.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Conclusion of rebate contracts for Empagliflozin as per § 130c SGB V.
- Standardized contract terms; no individual negotiations.
Show full summary
Open House procedure for concluding rebate contracts (Rabattverträge) according to § 130c SGB V for the active ingredient Empagliflozin. The procedure is open to all eligible pharmaceutical entrepreneurs, with standardized contract terms and no exclusivity. The contract runs from July 1, 2025, to June 30, 2027. Participation is possible at any time during this period. No estimated contract value is provided.
Risks
No estimated contract value is disclosed, making it impossible to assess potential revenue.
Contract ends automatically upon patent expiry or loss of market exclusivity, which could shorten the contract term.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in § 4(18) AMG.
- Valid marketing authorization for the offered medicinal product.
Eligibility
- Self-declaration of eligibility and reliability required.
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2025-16 - Empagliflozin
Rebate contracts for the active ingredient Empagliflozin. The contract is open to all pharmaceutical entrepreneurs who meet the eligibility criteria. No individual negotiations; standardized conditions apply.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Empagliflozin zu schließen.
Value note
Show original TED data
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Empagliflozin zu schließen.
Procurement Details
- Publication date
- 22 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 334433-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated contract value is disclosed, making it impossible to assess potential revenue.
Contract ends automatically upon patent expiry or loss of market exclusivity, which could shorten the contract term.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications